Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

MLA

Hadji, Peyman, et al. “Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in Postmenopausal Women with Hormone Sensitive Breast Cancer: Joint Position Statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.” Journal of Bone Oncology, vol. 7, Mar. 2017, pp. 1–12. EBSCOhost, https://doi.org/10.1016/j.jbo.2017.03.001.

APA

Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., Roodman, G. D., Cooper, C., Langdahl, B., Palacios, S., Kanis, J., Al-Daghri, N., Nogues, X., Eriksen, E. F., Kurth, A., … Coleman, R. E. (2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. Journal of Bone Oncology, 7, 1–12. https://doi.org/10.1016/j.jbo.2017.03.001

Chicago

Hadji, Peyman, Matti S Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M Carola Zillikens, et al. 2017. “Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in Postmenopausal Women with Hormone Sensitive Breast Cancer: Joint Position Statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.” Journal of Bone Oncology 7 (March): 1–12. doi:10.1016/j.jbo.2017.03.001.